Back

Governance is key to controlling SARS-CoV-2's vaccine resistance

Okamoto, K. W.; Chaves, L. F.; Wallace, R.; Wallace, R. G.

2022-05-30 health policy
10.1101/2022.05.26.22275649 medRxiv
Show abstract

Little attention has been paid to governances impacts on the evolution of SARS-CoV-2, the virus that causes COVID-19. To evaluate such impacts on the evolution of vaccine resistance, we analyzed a stochastic compartmental model to quantify the risk a mutant strain capable of evading immunity emerges post-vaccine rollout. We calibrated the model with publicly available data for four territories in the Western Hemisphere qualitatively differing in pandemic interventions. The model shows an immune-evading strain to be readily selected over all infectivities in Texas. In Panama, only a high level of transmission permits immune evasion to evolve. No invasion appears likely in Costa Rica and Uruguay. Programs combining pharmaceutical and nonpharmaceutical interventions are best positioned to remove the epidemiological space SARS-CoV-2 needs to evolve vaccine resistance. One Sentence SummaryModes of governance and production help set the evolutionary trajectories of vaccine resistance in SARS-CoV-2 before vaccine campaigns begin.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Proceedings of the National Academy of Sciences
● 2130 papers in training set
Top 1%
18.6%
2
eLife
● 5422 papers in training set
Top 2%
14.3%
3
Science
● 429 papers in training set
Top 3%
8.4%
4
PNAS Nexus
◐ 147 papers in training set
Top 0.1%
6.8%
5
Nature
○ 575 papers in training set
Top 4%
6.8%
50% of probability mass above
6
Nature Human Behaviour
○ 85 papers in training set
Top 0.5%
4.8%
7
Nature Medicine
○ 117 papers in training set
Top 0.7%
3.9%
8
iScience
○ 1063 papers in training set
Top 5%
3.6%
9
Cell
○ 370 papers in training set
Top 7%
3.1%
10
Cell Systems
○ 167 papers in training set
Top 5%
2.4%
11
Nature Genetics
○ 240 papers in training set
Top 4%
1.9%
12
Nature Communications
○ 4913 papers in training set
Top 50%
1.8%
13
Neuron
○ 282 papers in training set
Top 6%
1.7%
14
Nature Aging
○ 51 papers in training set
Top 1%
1.5%
15
Scientific Reports
○ 3102 papers in training set
Top 66%
1.2%
16
Science Advances
● 1098 papers in training set
Top 25%
0.9%
17
Proceedings of the Royal Society B: Biological Sciences
● 341 papers in training set
Top 6%
0.9%
18
Current Biology
○ 596 papers in training set
Top 13%
0.9%
19
PLOS ONE
● 4510 papers in training set
Top 64%
0.9%
20
The Lancet Infectious Diseases
○ 71 papers in training set
Top 3%
0.7%
21
COVID
○ 13 papers in training set
Top 0.3%
0.7%
22
PLOS Biology
● 408 papers in training set
Top 21%
0.7%
23
Epidemics
○ 104 papers in training set
Top 2%
0.7%
24
Nature Structural & Molecular Biology
○ 218 papers in training set
Top 5%
0.7%
25
Nature Microbiology
○ 133 papers in training set
Top 5%
0.6%
26
Biology Direct
○ 10 papers in training set
Top 0.1%
0.6%
27
Neural Networks
○ 32 papers in training set
Top 0.9%
0.6%
28
Advanced Science
○ 249 papers in training set
Top 22%
0.6%
29
Virus Evolution
◐ 140 papers in training set
Top 2%
0.6%
30
Mathematical Biosciences
○ 42 papers in training set
Top 1%
0.6%